Clinical research
The announcement for the chikungunya vaccine (VLA1553) comes after the U.S. FDA awarded it with a Breakthrough Designation status. Read more about it here.
Pfizer said that the Phase IIb/III ALLEGRO trial on ritlecitinib was found to be effective against the autoimmune disease, which is characterized by an immune attack on hair follicles.
With this milestone, the field is now wide open for the next in vivo CRISPR success, and Editas is hoping that it will be in the ocular disease space.
The FDA-initiated partial hold on Novartis’ gene therapy trial for spinal muscular atrophy has been lifted recently. Here’s everything you need to know about it.
Sage announced the termination of the REDWOOD and RAINFOREST studies of zuranolone, which is being assessed to treat both major depressive disorder and post-partum depression.
Shares in the company climbed more than 30% premarket following the news of the study findings. The major reason is believed to be the performance of bevacizumab.
The company announced that it is withdrawing its peripheral T-cell lymphoma drug Istodax from the market after recent trials showed that it does not achieve its primary efficacy endpoint.
Late-phase trial data show Servier’s TIBSOVO, in conjunction with chemotherapy azacitidine, prolonged event-free survival in adult patients with previously untreated IDH1-mutated acute myeloid leukemia.
The drug, created by Vaxart, has just completed its Phase I trial and had submitted an Investigational New Drug application to move forward.
The company saw global net revenue of $13.9 billion during the second quarter, an increase of 33.9%. Sales were primarily driven by its immunology portfolio, which generated $6.12 billion.
PRESS RELEASES